December 17, 2024 8:06am
Chances for a Tuesday runs batted in ...
Pre-open Indications: 4 Positive Indications
NOT much has changed, as I have written, “uncle algo and his trading dwarfs” determine the heights or lows of share pricing”
Never leave an investor uninform
Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.
My interpretation of the morning’s numbers is written to be informative; it’s built on what happened or will happen behind the headline today!
Monday’s night’s update … RegMed Investors (RMi) Closing Bell: pop goes the sector … https://www.regmedinvestors.com/articles/13737
Tuesday The pre-open Dow futures are DOWN -0.41% or (-180 points), the S&P futures are DOWN -0.34% or (-21 points) and the Nasdaq futures are DOWN -0.24% or (-54 points)
- Stock futures fell Tuesday,
- European markets traded in negative territory,
- Asia-Pacific markets were mixed,
Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies
Traders await the Fed’s next rate decision, slated at the conclusion of the central bank’s final 2024 2-day policy meeting Wednesday; as the gathering kicks off Tuesday.
Monday: The Dow closed DOWN -110.34 points or -0.25%, the S&P closed UP +22.99 points or +0.38% while the Nasdaq closed UP +247.17 points or +1.24%
- Monday’s advance/decline line ended with a positive close at the close of 21 incliner, 11 decliners and 3 flats
Economic Data Docket: for November -U.S. retail sales, Retail sales minus autos , Industrial production, Capacity utilization, Home Builder Confidence index for Dec.
Q4/24: December = 8 negative and 3 positive closes
- November 10 negative and 9 positive closes
- October: 8 positive and 15 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context
I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.
A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.
Positive indications:
Monday, Friday, Thursday, Wednesday, Tuesday, and last Monday’s closing “numbers” with aftermarket/pre-market dollar ($) and cent ($0.00) value and percentage (%)
Beam Therapeutics (BEAM) closed up +1.00 after Friday’s -$0.13, Thursday’s -$0.84, Wednesday’s -$1.30 and last Tuesday’s +$2.69 and the previous Monday’s +$0.81 with a positive +$0.86 or +2.97% pre-open.
CRISPR Therapeutics (CRSP) closed up +$0.46 after Friday’s $2.38 with a positive +$0.15 or +0.34% aftermarket
Vericel (VCEL) closed down -1.01 after Friday’s +$0.46 with a positive +$0.43 or +0.75% pre-market.
Ultragenyx Pharmaceuticals (RARE) closed down again -$0.38 after Friday’s -$1.11 and Thursday’s -$1.97 with a positive +1.20 or +2.46% pre-market
The BOTTOM LINE: We have survived last and the previous weeks momentum reversals … via downdrafts.
As I am STILL suspicious of the sector’s “froth” heading into this week ends as it runs.
There are clear winners with mostly losers in December …
- Think about it; the biggest problem the cell and gene therapy sector has … 99% of them have no earnings! If rates are higher for longer, that means that sector companies will continue to struggle or be unable to raise capital and therefore be subject to debt servicing firms!
I seem to be asking a question followed by a question …
- Do we need to brace ourself for more economics and their down trending affect?
- Is this market STILL “bubblicious” my concerns are macroeconomic and valuation
Welcome to my world of defining the “grey’ in our universe!
- The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
- I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.
